Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice

To control G protein signaling in vivo, we have modified G protein–coupled receptors to respond exclusively to synthetic small molecule agonists and not to their natural agonist(s). These engineered receptors are designated RASSLs (receptor activated solely by a synthetic ligand). A prototype RASSL (Ro1) based on the Gi–coupled κ opioid receptor was expressed in transgenic mice under the control of the tetracycline transactivator (tet) system. Activation of Ro1 expressed in the heart decreased heart rate by up to 80%, an expected effect of increased Gi signaling. Maximal heart rate changes occurred in less than 1 min, demonstrating the speed of this inducible signaling system. This Ro1–mediated slowing of heart rate was also subject to desensitization, which lasted more than 24 h. Both the initial effect on heart rate and the desensitization occurred, even though Ro1 is derived from a human opioid receptor not normally involved in heart rate control. In addition, the tet system was used to induce Ro1 expression in hepatocytes and salivary gland, where Gi signaling is known to control physiologic events such as proliferation and secretion. These studies demonstrate that a RASSL can be inducibly expressed in several mouse tissues and used in vivo to activate G protein signaling in a controllable fashion.

[1]  C. Homcy,et al.  G Proteins in the Heart: A Redundant and Diverse Transmembrane Signaling Network , 1991, Circulation.

[2]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Weinstein,et al.  Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction. , 1992, Endocrine reviews.

[4]  P. Sótonyi,et al.  Increase in functional activity rather than in amount of Gi-alpha in failing human heart with dilated cardiomyopathy. , 1992, Cardiovascular research.

[5]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[6]  Y Wang,et al.  A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Steinfath,et al.  Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. , 1994, Journal of molecular and cellular cardiology.

[8]  J. Benovic,et al.  Regulation of G protein-coupled receptors by receptor kinases and arrestins. , 1995, Vitamins and hormones.

[9]  R. Lefkowitz,et al.  Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.

[10]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Böhm,et al.  Heterotrimeric G proteins in heart disease. , 1996, Cellular signalling.

[12]  D. M. Spencer Creating conditional mutations in mammals. , 1996, Trends in genetics : TIG.

[13]  G. Fishman,et al.  Conditional transgene expression in the heart. , 1996, Circulation research.

[14]  G. Newton,et al.  Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. , 1996, The Journal of clinical investigation.

[15]  M. Gossen,et al.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Schreiber,et al.  Dimeric ligands define a role for transcriptional activation domains in reinitiation , 1996, Nature.

[17]  M. Farrar,et al.  Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization , 1996, Nature.

[18]  L. Hennighausen,et al.  Time-Sensitive Reversal of Hyperplasia in Transgenic Mice Expressing SV40 T Antigen , 1996, Science.

[19]  Agonist-induced phosphorylation of the kappa-opioid receptor. , 1997, Journal of neurochemistry.

[20]  H. Akil,et al.  Controlling signaling with a specifically designed Gi-coupled receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R Kuhn,et al.  Temporally and spatially regulated somatic mutagenesis in mice. , 1998, Nucleic acids research.

[22]  B. Roques,et al.  Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.